Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation

Inaugural consensus statements were developed and endorsed by the American College of Radiology (ACR) National Kidney Foundation to improve standardize care patients with kidney disease who have indication(s) receive ACR-designated group II or III intravenous gadolinium-based contrast media (GBCM). The risk nephrogenic systemic fibrosis (NSF) from GBCM in advanced is thought be very low (zero events following 4931 administrations estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2; upper bounds 95% confidence intervals: 0.07% overall, 0.2% for stage 5D chronic [CKD], 0.5% 5 CKD no dialysis). No unconfounded cases NSF been reported only available (gadoxetate disodium). Depending on clinical indication, potential harms delaying withholding an MRI a patient acute injury eGFR less than 30 m2 should balanced against may outweigh NSF. Dialysis initiation alteration likely unnecessary based administration. This article simultaneous joint publication Medicine. articles are identical except stylistic changes keeping each journal’s style. Either version used citing this article. © 2020 RSNA published Elsevier Inc. open access under CC BY NC-ND license.